These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14616436)

  • 1. The management of hormone-relapsed prostate cancer.
    Clarke NW
    BJU Int; 2003 Nov; 92(8):860-8. PubMed ID: 14616436
    [No Abstract]   [Full Text] [Related]  

  • 2. Manifestations of advanced prostate cancer: prognosis and treatment.
    Surya BV; Provet JA
    J Urol; 1989 Oct; 142(4):921-8. PubMed ID: 2677414
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of life of patients with advanced and metastatic prostatic carcinoma.
    Villavicencio H
    Eur Urol; 1993; 24 Suppl 2():118-21. PubMed ID: 8262116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of hormone-relapsed prostate cancer.
    Parkinson RW; Austin RH; Parr NJ
    BJU Int; 2004 May; 93(7):1115. PubMed ID: 15142178
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of pain and other symptoms of advanced prostatic cancer.
    Labasky RF; Smith JA
    Semin Urol; 1988 Nov; 6(4):311-21. PubMed ID: 3068769
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metastases--the clinical problem.
    Rubens RD
    Eur J Cancer; 1998 Feb; 34(2):210-3. PubMed ID: 9741323
    [No Abstract]   [Full Text] [Related]  

  • 8. Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
    Scher HI
    Eur Urol; 1996; 29 Suppl 2():40-4. PubMed ID: 8717462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.
    Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Bril H; Papapoulos SE; Hamdy NA
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):958-63. PubMed ID: 14985870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of estramustine phosphate on hormone refractory prostate cancer].
    Tanaka M; Shiomi K; Hamano S; Suzuki N; Igarashi T; Murakami S; Shimazaki J
    Hinyokika Kiyo; 1997 Mar; 43(3):245-50. PubMed ID: 9127765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premature conclusions may harm good ideas.
    Staudenherz A; Sinzinger H
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):625-6; author reply 627. PubMed ID: 15723225
    [No Abstract]   [Full Text] [Related]  

  • 12. Palliative care in urology.
    Wu JN; Meyers FJ; Evans CP
    Surg Clin North Am; 2011 Apr; 91(2):429-44, x. PubMed ID: 21419262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing skeletal related events resulting from bone metastases.
    Wilkinson AN; Viola R; Brundage MD
    BMJ; 2008 Nov; 337():a2041. PubMed ID: 18981017
    [No Abstract]   [Full Text] [Related]  

  • 14. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute renal failure in a patient with chronic glomerulonephritis after the administration of luteinizing hormone-releasing hormone analogue given for rectal obstruction due to prostate cancer.
    Takezawa Y; Nakano K; Ohtake N; Yamanaka H
    Int J Urol; 1996 Jan; 3(1):67-9. PubMed ID: 8646604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
    Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of advanced prostate cancer.
    Smith JA; Soloway MS; Young MJ
    Urology; 1999 Dec; 54(6A Suppl):8-14. PubMed ID: 10606278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incomplete rectal obstruction secondary to adenocarcinoma of the prostate.
    Desai PA; Fioerelli RL; Finkelstein LH
    J Am Osteopath Assoc; 1991 Aug; 91(8):803-6. PubMed ID: 1744011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliation of malignant rectal obstruction from invasive prostate cancer with multiple overlapping self-expanding metal stents.
    Smith AS; Cole M; Vega KJ; Munoz JC
    South Med J; 2009 Dec; 102(12):1257-9. PubMed ID: 20016435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.